奥泰生物: 关于调整2024年限制性股票激励计划授予价格的公告

Core Viewpoint - The company has adjusted the grant price of its 2024 restricted stock incentive plan from 29.24 CNY per share to 26.2993 CNY per share due to the implementation of its profit distribution plan [1][5][6] Group 1: Adjustment Details - The adjustment of the grant price was approved by the company's board and supervisory board during their respective meetings [1][2] - The adjustment was made in accordance with the company's 2024 restricted stock incentive plan and the authorization from the second extraordinary general meeting of shareholders [1][5] - The adjusted grant price reflects the cash dividends distributed to shareholders, calculated as follows: P = P0 - V, where P0 is the original grant price and V is the cash dividend per share [4][5] Group 2: Financial Impact - The adjustment of the grant price is not expected to have a substantial impact on the company's financial condition or operating results [5][6] - The adjustment will not affect the stability of the management team or the continued implementation of the incentive plan [5][6] Group 3: Opinions from Supervisory and Compensation Committees - The supervisory board agrees that the adjustment complies with relevant laws and regulations and does not harm the interests of the company and all shareholders [5][6] - The compensation and assessment committee of the board also supports the adjustment, confirming its compliance with the management regulations and the incentive plan [6]